Clinical Scenario
This protocol applies to pregnant women with a known prolactinoma. Pregnancy represents a distinct clinical context that requires careful re-evaluation of how prolactinoma is managed, particularly when a dopamine agonist was part of the patient's care prior to conception.
Key Considerations During Pregnancy
For patients with macroadenomas who become pregnant while on a dopamine agonist and who have not had prior therapy, the approach to continued treatment depends on individual tumor characteristics — including whether the tumor is invasive or anatomically close to critical structures. In cases where symptomatic tumor growth occurs during pregnancy, specific pharmacological therapy is indicated, with bromocriptine as the treatment of choice in that setting.
The complete decision algorithm, patient-selection criteria, and management sequence are available in the full structured protocol.
References
DOI: 10.1210/clinem/dgad174
The low risk of tumor enlargement during pregnancy has provided the reason why women with prolactinomas must be instructed to withdraw DA as soon as pregnancy is confirmed (34, 55), as in clinical case 2.
Nevertheless, in selected patients with macroadenomas who become pregnant while on DA and who have not had prior therapy, it may be cautious to continue DA throughout the pregnancy, especially if the tumor is invasive or abutting the optic chiasm.
In patients experiencing symptomatic growth of a prolactinoma during pregnancy treatment restarting is recommended, and bromocriptine is the therapy of choice, based on the large experience over years not documenting any increased risk for maternal and foetal outcomes.
View source ↗